Beta Drugs Reports Strong Q1FY27 Results Driven by Oncology Growth and Efficient Operations
Beta Drugs Limited has reported robust consolidated financial results for the first quarter of fiscal year 2027 (Q1FY27), demonstrating significant growth across its key business segments. The company recorded total sales of Rs 125.55 crores, marking a substantial 25.3% increase from the Rs 100.2 crores reported in the previous fiscal year. Total revenues reached Rs 127.13 crores.The quarterly performance was underpinned by stellar growth in branded oncology and CMO (Contract Manufacturing Organization) services. The branded oncology business delivered a 47% year-on-year growth, contributing sales of INR 33.0 Crores. The CMO segment also showed...